Dr. Skinner is a Managing Director for the Novartis Venture Funds in Cambridge, MA, USA. Prior to the Novartis Venture Funds, he worked as Executive Director and Global Head Strategic Alliances, Therapeutics and Head Strategic Alliances, Technologies at the Novartis Institutes for Biomedical Research, where he led a team responsible for identification, negotiation and management of collaborations and licenses for Novartis’ therapeutic areas as well as the technology areas. Prior to joining Novartis, he was CEO of SelectX Pharmaceuticals and President and CEO of NeoGenesis Pharmaceuticals, which was acquired by Schering-Plough. He was also Director of Technology Acquisitions for Pharmacia & Upjohn and Pharmacia, managing business development and licensing for Pharmacia’s research platforms and therapeutic areas worldwide, and Director of Business Development at Lexicon Genetics. He was a postdoctoral fellow at Baylor College of Medicine in the department of Human and Molecular Genetics and earned his PhD in microbiology and MS in biochemistry from the University of Illinois. Henry serves on the board of Avila, and works with Cylene, Forma, and Merus.

Molecular Genetics,microbiology,biochemistry